Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial
Authors:
- Xavier BoschXBXavier Bosch
- Jordi EsteveJEJordi Esteve
- Marta SitgesMSMarta Sitges
- Teresa M. de CaraltTCTeresa M. de Caralt
- Ariadna DomènechADAriadna Domènech
- José T. OrtizJOJosé T. Ortiz
- Mariano MonzóMMMariano Monzó
- Manuel Morales-RuizMMManuel Morales-Ruiz
- Rosario J. PereaRPRosario J. Perea
- Montserrat RoviraMRMontserrat Rovira
- 31 August 2011
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 17 (8) , 643-648
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult MiceCirculation, 2010
- Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell FunctionCirculation, 2010
- Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac functionHeart, 2007
- Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and managementExpert Opinion on Pharmacotherapy, 2007
- Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantationEuropean Journal of Haematology, 2006
- Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and RecommendationsJNCI: Journal of the National Cancer Institute, 2006
- Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantationCancer, 2005
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialJournal of Clinical Oncology, 2004
- Cardiovascular Complications of Cancer TherapyCirculation, 2004